Related references
Note: Only part of the references are listed.Mutant α-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity:: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin
Satoshi Ishii et al.
BIOCHEMICAL JOURNAL (2007)
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis
Gustavo H. B. Maegawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Pharmacological enhancement of mutated α-glucosidase activity in fibroblasts from patients with Pompe disease
Giancarlo Parenti et al.
MOLECULAR THERAPY (2007)
High-throughput screening for human lysosomal β-N-acetyl hexosaminidase inhibitors acting as pharmacological chaperones
Michael B. Tropak et al.
CHEMISTRY & BIOLOGY (2007)
Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II
Toshika Okumiya et al.
MOLECULAR GENETICS AND METABOLISM (2007)
α-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease
Liang Yu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms
Richard A. Steet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients
Hui-Hwa Chang et al.
FEBS JOURNAL (2006)
Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease
Philippe Compain et al.
CHEMBIOCHEM (2006)
Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease
M Schmitz et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles
AR Sawkar et al.
CHEMISTRY & BIOLOGY (2005)
ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity
I Ron et al.
HUMAN MOLECULAR GENETICS (2005)
A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder
GHF Yam et al.
FASEB JOURNAL (2005)
Rational design and synthesis of highly potent beta-glucocerebrosidase inhibitors
XX Zhu et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2005)
Gene therapy for lysosomal storage diseases: the lessons and promise of animal models
NM Ellinwood et al.
JOURNAL OF GENE MEDICINE (2004)
Pharmacological enhancement of β-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients
MB Tropak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Pharmacological chaperones:: potential treatment for conformational diseases
V Bernier et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2004)
Pharmacologic rescue of conformationally-defective proteins: Implications for the treatment of human disease
A Ulloa-Aguirre et al.
TRAFFIC (2004)
Roles of N-linked glycans in the endoplasmic reticulum
A Helenius et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease
UH Schueler et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2004)
Treatment of lysosomal storage disorders: Cell therapy and gene therapy
Y Eto et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2004)
Chemical chaperone therapy for brain pathology in GM1-gangliosidosis
J Matsuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Therapeutic approaches to protein-misfolding diseases
FE Cohen et al.
NATURE (2003)
A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity
JQ Fan
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
Quality control in the endoplasmic reticulum
L Ellgaard et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement
TM Cox et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Chemical chaperones increase the cellular activity of N370S β-glucosidase:: A therapeutic strategy for Gaucher disease
AR Sawkar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Chemical modification of the β-glucocerebrosidase inhibitor N-octyl-β-valienamine:: Synthesis and biological evaluation of 4-epimeric and 4-O-(β-D-galactopyranosyl) derivatives
S Ogawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2002)
Protein folding - Molecular chaperones in the cytosol: from nascent chain to folded protein
FU Hartl et al.
SCIENCE (2002)
New prospects for the treatment of lysosomal storage diseases
R Schiffmann et al.
DRUGS (2002)
Brief report: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy.
A Frustaci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation
GC Meacham et al.
NATURE CELL BIOLOGY (2001)
Novel alpha-L-fucosidase inhibitors from the bark of Angylocalyx pynaertii (Leguminosae)
N Asano et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives
N Asano et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
T Cox et al.
LANCET (2000)
Share Paper
